Bcr-Abl inhibition as a modality of CML therapeutics
- 1 August 2001
- journal article
- review article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1551 (1) , M11-M18
- https://doi.org/10.1016/s0304-419x(01)00022-1
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- The molecular biology of chronic myeloid leukemiaBlood, 2000
- Chronic Myelogenous Leukemia: Biology and TherapyAnnals of Internal Medicine, 1999
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- Acute leukaemia in bcr/abl transgenic miceNature, 1990
- Induction of Chronic Myelogenous Leukemia in Mice by the P210
bcr/abl
Gene of the Philadelphia ChromosomeScience, 1990
- Expression of a Distinctive BCR-ABL Oncogene in Ph 1 -Positive Acute Lymphocytic Leukemia (ALL)Science, 1988
- The Chronic Myelogenous Leukemia-Specific P210 Protein Is the Product of the bcr / abl Hybrid GeneScience, 1986
- Fused transcript of abl and bcr genes in chronic myelogenous leukaemiaNature, 1985
- A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemiaNature, 1982
- A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa StainingNature, 1973